Selected research
Industry Growth & Trends
Global Pet Biopharmaceuticals Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Pet Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Pet Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Pet Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pet Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Pet Biopharmaceuticals market include Merck, Zoetis, Virbac, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Elanco and Dechra Veterinary Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Pet Biopharmaceuticals market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Pet Biopharmaceuticals market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pet Biopharmaceuticals market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pet Biopharmaceuticals.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Pet Biopharmaceuticals market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Pet Biopharmaceuticals Market by Company
Merck
Zoetis
Virbac
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Elanco
Dechra Veterinary Products
Chopperlvya Animal Health
Ceva
CAHIC
Boehringer Ingelheim
Pet Biopharmaceuticals Segment by Type
Antiparasitic
Antibacterial
Biological Products
Others
Pet Biopharmaceuticals Segment by Application
Prevention
Treatment
Pet Biopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pet Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Biopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Pet Biopharmaceuticals companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Antiparasitic
- Antibacterial
- Biological Products
- Others
Applications
- Prevention
- Treatment
Companies covered
- Merck
- Zoetis
- Virbac
- Vetoquinol
- Ouro Fino Saude
- Norbrook
- Jindun
- Elanco
- Dechra Veterinary Products
- Chopperlvya Animal Health
- Ceva
- CAHIC
- Boehringer Ingelheim
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Pet Biopharmaceuticals Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Pet Biopharmaceuticals Market Size by Region (2021-2032)
- 1.4.1 Global Pet Biopharmaceuticals Market Size by Region (2021-2026)
- 1.4.2 Global Pet Biopharmaceuticals Market Size by Region (2027-2032)
- 1.5 Key Regions Pet Biopharmaceuticals Market Size (2021-2032)
- 1.5.1 North America Pet Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Pet Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Pet Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.4 South America Pet Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Pet Biopharmaceuticals Market Size Growth Rate (2021-2032)
2 Pet Biopharmaceuticals Market by Type
- 2.1 Type Introduction
- 2.1.1 Antiparasitic
- 2.1.2 Antibacterial
- 2.1.3 Biological Products
- 2.1.4 Others
- 2.2 Global Pet Biopharmaceuticals Market Size by Type
- 2.2.1 Global Pet Biopharmaceuticals Market Size Overview by Type (2021-2032)
- 2.2.2 Global Pet Biopharmaceuticals Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Pet Biopharmaceuticals Market Size Forecasted by Type (2027-2032)
- 2.3 Global Pet Biopharmaceuticals Market Size by Regions
- 2.3.1 North America Pet Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Pet Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Pet Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Pet Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Pet Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
3 Pet Biopharmaceuticals Market by Application
- 3.1 Type Introduction
- 3.1.1 Prevention
- 3.1.2 Treatment
- 3.2 Global Pet Biopharmaceuticals Market Size by Application
- 3.2.1 Global Pet Biopharmaceuticals Market Size Overview by Application (2021-2032)
- 3.2.2 Global Pet Biopharmaceuticals Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Pet Biopharmaceuticals Market Size Forecasted by Application (2027-2032)
- 3.3 Global Pet Biopharmaceuticals Market Size by Regions
- 3.3.1 North America Pet Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Pet Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Pet Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Pet Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Pet Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Pet Biopharmaceuticals Industry Trends
- 4.2 Pet Biopharmaceuticals Industry Drivers
- 4.3 Pet Biopharmaceuticals Industry Opportunities and Challenges
- 4.4 Pet Biopharmaceuticals Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Pet Biopharmaceuticals Revenue (2021-2026)
- 5.2 Global Pet Biopharmaceuticals Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Pet Biopharmaceuticals Key Company Headquarters & Area Served
- 5.4 Global Pet Biopharmaceuticals Company, Product Type & Application
- 5.5 Global Pet Biopharmaceuticals Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Pet Biopharmaceuticals Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Pet Biopharmaceuticals Players Market Share by Revenue in 2025
- 5.6.3 2025 Pet Biopharmaceuticals Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Merck
- 6.1.1 Merck Company Information
- 6.1.2 Merck Business Overview
- 6.1.3 Merck Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Merck Pet Biopharmaceuticals Product Portfolio
- 6.1.5 Merck Recent Developments
- 6.2 Zoetis
- 6.2.1 Zoetis Company Information
- 6.2.2 Zoetis Business Overview
- 6.2.3 Zoetis Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Zoetis Pet Biopharmaceuticals Product Portfolio
- 6.2.5 Zoetis Recent Developments
- 6.3 Virbac
- 6.3.1 Virbac Company Information
- 6.3.2 Virbac Business Overview
- 6.3.3 Virbac Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Virbac Pet Biopharmaceuticals Product Portfolio
- 6.3.5 Virbac Recent Developments
- 6.4 Vetoquinol
- 6.4.1 Vetoquinol Company Information
- 6.4.2 Vetoquinol Business Overview
- 6.4.3 Vetoquinol Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Vetoquinol Pet Biopharmaceuticals Product Portfolio
- 6.4.5 Vetoquinol Recent Developments
- 6.5 Ouro Fino Saude
- 6.5.1 Ouro Fino Saude Company Information
- 6.5.2 Ouro Fino Saude Business Overview
- 6.5.3 Ouro Fino Saude Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Ouro Fino Saude Pet Biopharmaceuticals Product Portfolio
- 6.5.5 Ouro Fino Saude Recent Developments
- 6.6 Norbrook
- 6.6.1 Norbrook Company Information
- 6.6.2 Norbrook Business Overview
- 6.6.3 Norbrook Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Norbrook Pet Biopharmaceuticals Product Portfolio
- 6.6.5 Norbrook Recent Developments
- 6.7 Jindun
- 6.7.1 Jindun Company Information
- 6.7.2 Jindun Business Overview
- 6.7.3 Jindun Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Jindun Pet Biopharmaceuticals Product Portfolio
- 6.7.5 Jindun Recent Developments
- 6.8 Elanco
- 6.8.1 Elanco Company Information
- 6.8.2 Elanco Business Overview
- 6.8.3 Elanco Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Elanco Pet Biopharmaceuticals Product Portfolio
- 6.8.5 Elanco Recent Developments
- 6.9 Dechra Veterinary Products
- 6.9.1 Dechra Veterinary Products Company Information
- 6.9.2 Dechra Veterinary Products Business Overview
- 6.9.3 Dechra Veterinary Products Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Dechra Veterinary Products Pet Biopharmaceuticals Product Portfolio
- 6.9.5 Dechra Veterinary Products Recent Developments
- 6.10 Chopperlvya Animal Health
- 6.10.1 Chopperlvya Animal Health Company Information
- 6.10.2 Chopperlvya Animal Health Business Overview
- 6.10.3 Chopperlvya Animal Health Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Chopperlvya Animal Health Pet Biopharmaceuticals Product Portfolio
- 6.10.5 Chopperlvya Animal Health Recent Developments
- 6.11 Ceva
- 6.11.1 Ceva Company Information
- 6.11.2 Ceva Business Overview
- 6.11.3 Ceva Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Ceva Pet Biopharmaceuticals Product Portfolio
- 6.11.5 Ceva Recent Developments
- 6.12 CAHIC
- 6.12.1 CAHIC Company Information
- 6.12.2 CAHIC Business Overview
- 6.12.3 CAHIC Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 CAHIC Pet Biopharmaceuticals Product Portfolio
- 6.12.5 CAHIC Recent Developments
- 6.13 Boehringer Ingelheim
- 6.13.1 Boehringer Ingelheim Company Information
- 6.13.2 Boehringer Ingelheim Business Overview
- 6.13.3 Boehringer Ingelheim Pet Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Boehringer Ingelheim Pet Biopharmaceuticals Product Portfolio
- 6.13.5 Boehringer Ingelheim Recent Developments
7 North America
- 7.1 North America Pet Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 7.3 North America Pet Biopharmaceuticals Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Pet Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 8.3 Europe Pet Biopharmaceuticals Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Pet Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Pet Biopharmaceuticals Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Pet Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 10.3 South America Pet Biopharmaceuticals Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Pet Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Pet Biopharmaceuticals Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Pet Biopharmaceuticals Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst